Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALO-02 in chronic low back pain
NCT01571362Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxycodone in chronic low back pain (CLBP) (2 arms), sponsored by Pfizer. Primary endpoint: Change in Weekly Average Electronic Diary Numeric Rating Scale - Pain Score. Started Jun 2012; status: completed.
02
Drugs
oxycodone
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT01571362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571362.